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Sickle cell disease affects more than 100,000 individuals in the United
States, among whom disease severity varies considerably. One factor that
influences disease severity is the sickle cell disease genotype. For this reason,
clinical prevention and treatment guidelines tend to differentiate between
genotypes. However, previous research suggests caution when using a claimsbased determination of sickle cell disease genotype in healthcare quality
studies.
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The objective of this study was to describe the extent of miscoding for
the major sickle cell disease genotypes in hospital discharge data. Individuals
with sickle cell disease were identified through newborn screening results
or hemoglobinopathy specialty care centers, along with their sickle cell
disease genotypes. These genotypes were compared to the diagnosis codes
listed in hospital discharge data to assess the accuracy of the hospital codes
in determining sickle cell disease genotype. Eighty-three percent (sickle cell
anemia), 23% (Hemoglobin SC), and 31% (Hemoglobin Sβ+ thalassemia)
of hospitalizations contained a diagnosis code that correctly reflected the
individual’s true sickle cell disease genotype. The accuracy of the sickle
cell disease genotype coding was indeterminate in 11% (sickle cell anemia),
12% (Hemoglobin SC), and 7% (Hemoglobin Sβ+ thalassemia) and incorrect
in 3% (sickle cell anemia), 61% (Hemoglobin SC), and 52% (Hemoglobin Sβ+
thalassemia) of the hospitalizations. The use of ICD-9-CM codes from hospital
discharge data for determining specific sickle cell disease genotypes is
problematic. Research based solely on these or other types of administrative
data could lead to incorrect understanding of the disease.

Background
Sickle cell disease (SCD) is characterized by chronic hemolytic
anemia and a wide variety of acute and chronic complications
caused by intermittent episodes of vaso-occlusion, vascular injury,
and organ damage. SCD affects more than 100,000 individuals in the
United States1 and with recent advances in care, individuals with
SCD are living longer2. Even so, disease severity varies considerably
among individuals. While some exhibit severe complications and
die before reaching middle age, others are far less symptomatic3.

One factor that influences disease severity is the SCD genotype.
In the United States, most individuals with SCD have homozygous
hemoglobin (Hb) SS disease (Hb SS), and the remainder have a
compound heterozygous form of SCD caused by co-inheritance of
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Hb S with a different beta globin mutation such as Hb C or a
variety of β thalassemia mutations4. The Hb Sβ thalassemias
are divided into two groups depending on the severity of
the β thalassemia mutation; mutations that result in absent
production of β globin are termed Hb Sβ0 thalassemia while
those that result in reduced, but not absent, production of
β globin are termed Hb Sβ+ thalassemia. Individuals with
Hb SS or Hb Sβ0 thalassemia are classified as having sickle
cell anemia (SCA) because their hematological phenotype
is characterized by a more severe chronic hemolytic
anemia than those with Hb SC or Hb Sβ+ thalassemia,
who have less hemolysis and less severe or no anemia.
In the United States, Hb SC is the most prevalent of the
compound heterozygous SCD genotypes, followed by Hb
Sβ+ thalassemia and then Hb Sβ0 thalassemia. A recent
population-based surveillance study from six states found
that 61.4% of individuals with SCD had SCA, 28.3% had Hb
SC, 8.5% had Hb Sβ+ thalassemia, and 1.8% had another
compound heterozygous form of SCD5.
It is sometimes difficult to distinguish between the two
SCA genotypes because the co-inheritance of α thalassemia
in persons with Hb SS results in significant overlap of
complete blood count and hemoglobin electrophoresis
results in persons with Hb Sβ0 thalassemia. Therefore, the
genotypes cannot be reliably differentiated without DNA
analysis. However, the distinction between SCA and Hb SC/
Hb Sβ+ thalassemia is important because the risk for some
of the more severe complications of SCD, such as stroke,
is much higher in SCA than in Hb SC/Hb Sβ+ thalassemia,
especially during childhood6. For this reason, clinical
prevention and treatment guidelines tend to differentiate
between genotypes in their practice recommendations
based on evidence of clinical effectiveness and differing
risk- benefit trade-offs. For example, annual transcranial
Doppler screening for prevention of stroke in childhood is
recommended for children with SCA but not for those with
Hb SC or Hb Sβ+ thalassemia. Similarly, indications for use
of hydroxyurea are much broader and more inclusive for
SCA compared to Hb SC or Hb Sβ+ thalassemia7.

International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) codes have
been commonly used by public health officials and health
services researchers to identify individuals with SCD to
evaluate complications, adherence to treatment guidelines,
and the quality of care received. Because researchers have
questioned the accuracy of SCD genotypes based on ICD-9CM codes8,9, studies usually identify patients based on any
SCD code (282.41-42, 282.6, 282.60-64, 282.68-69) in any
position, primary, secondary or other10-13. A few of these
studies have reported results by genotype, including reports
detailing rehospitalizations14, influenza15, stroke16, and
surgical outcomes for individuals with SCD17. Furthermore,
some studies have been restricted to individuals with

Hb SS codes only18-20 and others were limited to only
individuals with ICD-9-CM codes for SCD crisis21-24. In only
one instance has the accuracy of coding by SCD genotype
been reported25. In that report, findings from an analysis of
emergency department visits at a children’s hospital found
that ICD-9-CM codes for Hb SS were 87% accurate, but the
Hb SS codes were very often used for ED visits of patients
with other genotypes. Therefore, the authors suggested
caution when using a claims-based determination of SCD
genotype in healthcare quality studies.

Georgia and California have a unique set of SCD
surveillance data collected through the Registry and
Surveillance System for Hemoglobinopathies (RuSH)5.
These population-based data can be used to test the
accuracy of hospital discharge data for identifying SCD
genotypes and, in turn, their utility in evaluating adherence
to practice recommendations that differ by genotype. This
is possible by comparing ICD-9-CM codes from the hospital
discharge data to laboratory-based information collected
from clinical sites and state newborn screening programs
within the RuSH surveillance datasets. The purpose of
this study was to use the hospital discharge records of a
population-based sample to (1) describe the extent of
miscoding for the major SCD genotypes and estimate the
accuracy of ICD-9-CM codes and (2) report the positive
predictive value of using Hb SS ICD-9-CM codes only
(282.61 and 282.62) to identify individuals with SCA.

Methods

The methods that California and Georgia used to collect
and link population-based SCD surveillance data for 2004 to
2008 from a variety of sources were previously described5.
The analyses presented here include individuals with SCD
who were reported by newborn screening and/or one of
the participating hemoglobinopathy specialty treatment
centers (Georgia: Georgia Comprehensive Sickle Cell Center
at Grady Memorial, Georgia Health Sciences University, and
all three campuses of Children’s Healthcare of Atlanta;
California: University of California (UC) San Francisco
Benioff Children’s Hospital Oakland and San Francisco,
Children’s Hospital Los Angeles, UC Irvine Medical
Center, Rady UC San Diego, UC Davis Medical Center)
with a laboratory-confirmed diagnosis based on results of
clinical laboratory evaluation that included quantitative
hemoglobin identification by hemoglobin electrophoresis,
high-performance liquid chromatography or DNA analysis.
These individuals were then linked to inpatient files from
each state’s hospital discharge data (all records from 2004
to 2008) using multiple patient identifiers. This study only
included individuals who had at least one hospitalization
reported during the five year period.
The hospital discharge data from Georgia included
a maximum of ten diagnosis codes per admission; in
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the California data there were up to 25 diagnosis codes
per admission. All of the diagnosis codes were scanned
for the presence of an SCD ICD-9-CM code. These SCD
codes were then compared to the known SCD genotype
for the individual, and a determination of “correct,”
“indeterminate,” “incorrect,” or “no code” was made, based
on whether or not the diagnosis code and the known SCD
genotype were considered to be a correct match (Figure 1).
These categorizations were defined from the perspective
of the known SCD genotype. That is, for a hospitalization of
an individual with SCA, the “sickle-cell thalassemia with/
without crisis” (282.41, 282.42) ICD-9-CM codes would
be “correct” if the individual had Hb Sβ0 thalassemia, but
incorrect if the individual had Hb SS, so the comparison
was termed “indeterminate.” On the other hand, a
hospitalization of an individual with Hb Sβ+ thalassemia
would be termed “correct,” if the same codes were listed.

Hospital admissions for individuals with SCD genotypes
other than Hb SS/Hb Sβ0 thalassemia, Hb SC, or Hb Sβ+
thalassemia are provided in Table 1, but were excluded
ICD-9-CM Code

from further analyses (n=78 California; n=68 Georgia).
Admissions that included more than one SCD related ICD9-CM diagnosis code were also removed (n=18 California,
n=119 Georgia). The data analysis for this study was
generated using SAS® version 9.3 (SAS Institute, 2010).

Results

The RuSH surveillance project identified a total
of 6,264 individuals with a known SCD genotype in
California and Georgia; 1,976 in California and 4,288 in
Georgia. Of these, 3,961 (63.2%) accounted for a total of
27,439 hospitalizations during 2004 through 2008 (Table
1); 43.2% were for pediatric patients aged 18 years or
younger at the time of admission, and 46.8% were male
patients. Individuals with SCA accounted for 72.5% of the
patients with a known genotype and 79.9% of the hospital
discharges; Hb SC accounted for 21.4% of patients and
15.3% of discharges; Hb Sβ+ thalassemia accounted for
5.5% of patients and 4.2% of discharges.
ICD-9-CM coding correctly identified SCA genotypes
in 82.9% of hospitalizations (78.9% in CA, 84.5% in GA),
Sickle cell disease genotype

Sickle cell anemia

Hb SC

Hb Sβ+
thalassemia

282.41: Sickle-cell thalassemia without crisis
282.42: Sickle-cell thalassemia with crisis
282.6: Sickle-cell disease
282.60: Sickle-cell disease, unspeciﬁed
282.61: Hemoglobin-SS disease without crisis
282.62: Hemoglobin-SS disease with crisis
282.63: Sickle-cell/hemoglobin-C disease without
crisis
282.64: Sickle-cell/hemoglobin-C disease with
crisis
282.68: Other sickle-cell disease without crisis
282.69: Other sickle-cell disease with crisis

Correct = dots; indeterminate = horizontal lines; incorrect = crosshatch
Figure 1: Comparison of known sickle cell disease (SCD) genotype and SCD ICD-9-CM hospital discharge code, California and Georgia,
2004-2008.

Table 1: Description of patients with sickle cell disease and their hospital admissions, California and Georgia, 2004-2008.
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while the coding was incorrect in 3.4% (4.5% in CA, 2.9%
in GA) and indeterminate in 11.4% (15.4% in CA, 9.7% in
GA). However, coding for Hb SC was correct in only 22.8%
(24.4% in CA, 22.1% in GA) of hospitalizations, incorrect
in 60.9% (64.5% in CA, 59.3% in GA) and indeterminate
in 11.5% (8.0% CA, 13.1% GA). Individuals with Hb
Sβ+ thalassemia were correctly coded in only 30.5% of
hospitalizations overall; substantially higher in CA (56.2%)

than in GA (22.4%). Coding for Hb Sβ+ thalassemia was
incorrect in 52.2% (26.3% in CA, 60.3% in GA), and
indeterminate in 7.0% (6.6% in CA, 7.2% in GA) (Figure 2).
Two percent of hospitalizations for individuals with SCD in
California and 4% in Georgia did not contain an SCD ICD-9CM diagnosis code. The lack of any SCD diagnosis code was
higher for Hb Sβ+ thalassemia (10.3%) compared with Hb
SC (4.7%) and SCA (2.3%).

California
SCD ICD code is correct

SCD ICD code is indeterminant

SCD ICD code is incorrect

No SCD ICD code

100%
80%
60%
40%
20%
0%

Sickle cell anemia

Hb Sb+ thalassemia

Hb SC

0-18 years

19+ years

0-18 years

19+ years

0-18 years

n=3177

n=3012

n=501

n=772

n=189

n=85

ICD code is correct

2448 (77%)

2434 (81%)

211 (42%)

100 (13%)

116 (61%)

38 (45%)

ICD code is indeterminant
ICD code is incorrect

532 (17%)
171 (5%)

423 (14%)
107 (4%)

49 (10%)
224 (45%)

53 (7%)
597 (77%)

11 (6%)
38 (20%)

7 (8%)
34 (40%)

26 (1%)

48 (2%)

17 (3%)

22 (3%)

24 (13%)

6 (7%)

No SCD ICD code

19+ years

Figure 2a: Accuracy of ICD-9-CM hospital discharge codes for determining sickle cell disease genotype, California, 2004-2008.

Georgia
SCD ICD code is correct

SCD ICD code is indeterminant

SCD ICD code is incorrect

No SCD ICD code

Sickle cell anemia

Hb SC

100%
80%
60%
40%
20%
0%

Hb Sb+ thalassemia

0-18 years

19+ years

0-18 years

19+ years

0-18 years

n=6529

n=9113

n=1140

n=1782

n=204

19+ years
n=671

ICD code is correct

5302 (81%)

7918 (87%)

577 (51%)

69 (4%)

102 (50%)

94 (14%)

ICD code is indeterminant

703 (11%)

822 (9%)

134 (12%)

248 (14%)

6 (3%)

57 (8%)

ICD code is incorrect

180 (3%)

281 (3%)

328 (29%)

1406 (79%)

53 (26%)

475 (71%)

No SCD ICD code

344 (5%)

92 (1%)

101 (9%)

59 (3%)

43 (21%)

45 (7%)

Figure 2b: Accuracy of ICD-9-CM hospital discharge codes for determining sickle cell disease genotype, Georgia, 2004-2008.
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Table 2: Positive predictive value of using Hemoglobin SS ICD-9-CM hospital discharge codes (282.61 or 282.62) to identify individuals
with sickle cell anemia, California and Georgia, 2004-2008

In our cohort of hospitalizations for individuals with
SCD from both California and Georgia, using Hb SS ICD9-CM codes only (282.61, 282.62) versus any SCD code to
identify a pediatric patient with SCA improved the positive
predictive value (PPV) from 84% (9,850/11,740) to 93%
(7,750/8,306); however, in the adult population the PPV
only slightly improved from 79% (12,229/15,435) to 81%
(10,352/12,752) (Table 2).

Discussion

One of the most important distinctions to make, when
treating patients with SCD or evaluating their health and
healthcare utilization patterns, is between patients with SCA
genotypes and patients with other forms of SCD, because
patients with SCA are at a higher risk for many diseaserelated complications and hospitalization14,26. However,
the use of ICD-9-CM codes for determining specific SCD
genotypes is problematic for multiple reasons. First, although
it is sometimes difficult to distinguish Hb SS from Hb Sβ0
thalassemia based on results of hemoglobin electrophoresis
or other non DNA tests, there is no single ICD-9-CM code
for SCA, rather there are separate codes for “hemoglobin-SS
disease with/without crisis” (282.61, 282.62) and “sicklecell thalassemia with/without crisis” (282.41, 282.42).
Furthermore, the latter ICD-9-CM codes do not differentiate
between Hb Sβ° thalassemia and Hb Sβ+ thalassemia, the
former genotype causing SCA, while the latter does not.
The difficulty in distinguishing between SCA genotypes,
even with the presence of laboratory-based results, is the
reason that the SCD surveillance data collected by Georgia
and California, and used for the analyses presented here,
utilized an SCA classification, rather than separate Hb SS and
Hb Sβ0 thalassemia genotypes. Moreover, the limitations
of the ICD-9-CM codes for determining SCD genotypes
were the reason that the SCD surveillance data collected on
individuals without a newborn screening report or diagnosis
from a hemoglobinopathy specialty treatment center did not
contain genotype information and were, therefore, excluded
from this analysis.

In addition to the inherent limitations of the SCD ICD-9CM codes themselves, our study indicates that there is also
misuse of these codes, as has been previously reported25.
That study from a single pediatric emergency department
noted that the accuracy of correctly identifying individuals
with Hb SS was 87%, with sensitivity, specificity, and PPV
of 87%, 79%, and 87% respectively. Our study showed the
accuracy of identifying individuals with SCA in hospital
discharge data was similar. However the accuracy of ICD9-CM codes to identify other SCD genotypes was poor,
especially for individuals with Hb SC; over 75% of their
hospitalizations contained an ICD-9-CM code that did not
match their true SCD genotype. For Hb Sβ+ thalassemia,
accuracy was also low (69%). This miscoding may be,
in part, because some healthcare providers and coders
do not appreciate the differences among SCD genotypes,
leading to the use of Hb SS codes for non-Hb SS genotypes.
While these analyses were based on ICD-9-CM codes, it is
important to recognize that the ICD-10-CM codes for SCD
that are now being used have similar limitations.

The lack of SCA ICD-9-CM codes, ambiguous codes for Hb
Sβ0 thalassemia vs Hb Sβ+ thalassemia, and the high rates of
mismatch between true SCD genotype and the SCD ICD-9-CM
codes in hospital discharge data may lead to the erroneous
interpretation of such data and mistaken conclusions.
Using hospital discharge data to analyze hospital admission
and/or readmission rates, the rate of a particular surgical
procedure, or adherence to recommended therapy by
genotype could incorrectly classify up to 15% of individuals
with SCA, three-fourths of those with Hb SC, and over twothirds of those with Hb Sβ+ thalassemia. Errors such as these
could lead to incorrect understanding of the disease and
adherence to recommended management and treatment.
Our results suggest that caution should be exercised when
interpreting research that relies solely on hospital discharge
data to identify and determine the genotype of individuals
with SCD.
The results presented here further suggest that using
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only Hb SS ICD-9-CM codes to identify individuals with SCA
improves the genotypic accuracy of the resulting sample for
pediatric patients when compared to using all SCD ICD-9CM codes, but does little to improve identification of adults
with SCA. These results are due, in part, to the high rates
of miscoding for non-SCA genotypes, as well as the higher
rates of hospitalization in individuals with SCA (80% of the
SCD hospitalizations in this analysis, but only 73% of the
patients with a hospitalization and 64% of all identified
individuals with SCD, regardless of hospitalization).
A fundamental strength of this study is the identification
of cohort members through population-based surveillance,
rather than identification solely in administrative data or
a SCD specialty clinic(s). While the use of administrative
data alone requires fewer resources, it is often incomplete
and may suffer from suboptimal quality. Data from SCD
specialty clinics have higher quality and more complete
reporting, but contain a limited number of cases and may
not represent a population-based sample of all patients.

This analysis also has limitations. It has a narrow
focus on hospital discharge data, thus excluding the
37.7% of patients with known SCD genotypes who were
not hospitalized during the five year period. Results
from other commonly used administrative datasets, such
as Medicaid or emergency department claims data, may
show levels of congruence between true SCD genotype and
ICD-9-CM genotype that vary from the results presented
here. Furthermore, this study did not include individuals
with SCD for whom a laboratory-confirmed genotype was
not available. That is, the individuals who were neither
born in California or Georgia during the years of active
newborn screening nor receiving care from one of the
participating clinics. Finally, there were a large number
of hospitalizations during this five-year study period that
contained an SCD ICD-9-CM code, but were not linked to
our cohort.
These findings underscore the need for surveillance
systems that can accurately identify individuals living
with SCD along with their correct genotype, track their
health care utilization, and monitor their quality of care
by measuring adherence to practice guidelines in ways
that have the potential to reduce SCD associated morbidity
and mortality and improve care. Until a national registry
or other data collection system is available for SCD in the
US, researchers will be limited by the accuracy of ICD-9CM or, since late 2015, ICD-10-CM codes for determining
SCD genotype. Therefore, caution must be used when
interpreting results and applying findings to the
development of practice guidelines or recommendations
for clinical care.

Note

This project was reviewed by CDC and was determined

to be a non-research, public health practice activity. Both the
California Committee for Protection of Human Subjects and
the Georgia Public Health Department Institutional Review
Board declared the project exempt from review as a public
health surveillance effort; specialty hemoglobinopathy
treatment center institutional review boards similarly
exempted the project from review. State data requests were
reviewed by the appropriate agency, assuring data privacy
safeguards were in place. The findings and conclusions in
this report are those of the authors and do not necessarily
represent the official position of the Centers for Disease
Control and Prevention.
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